- Home
- RSF vs PRLD Comparison
RSF vs PRLD Comparison
Compare RSF & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- PRLD
- Stock Information
- Founded
- RSF 2016
- PRLD 2016
- Country
- RSF United States
- PRLD United States
- Employees
- RSF N/A
- PRLD N/A
- Industry
- RSF Investment Managers
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- RSF Finance
- PRLD Health Care
- Exchange
- RSF Nasdaq
- PRLD Nasdaq
- Market Cap
- RSF 62.5M
- PRLD 69.1M
- IPO Year
- RSF N/A
- PRLD 2020
- Fundamental
- Price
- RSF N/A
- PRLD $1.40
- Analyst Decision
- RSF
- PRLD Strong Buy
- Analyst Count
- RSF 0
- PRLD 3
- Target Price
- RSF N/A
- PRLD $4.00
- AVG Volume (30 Days)
- RSF 11.8K
- PRLD 284.3K
- Earning Date
- RSF 01-01-0001
- PRLD 11-05-2025
- Dividend Yield
- RSF 10.61%
- PRLD N/A
- EPS Growth
- RSF N/A
- PRLD N/A
- EPS
- RSF N/A
- PRLD N/A
- Revenue
- RSF N/A
- PRLD $7,000,000.00
- Revenue This Year
- RSF N/A
- PRLD N/A
- Revenue Next Year
- RSF N/A
- PRLD N/A
- P/E Ratio
- RSF N/A
- PRLD N/A
- Revenue Growth
- RSF N/A
- PRLD N/A
- 52 Week Low
- RSF $14.81
- PRLD $0.61
- 52 Week High
- RSF $16.23
- PRLD $2.08
- Technical
- Relative Strength Index (RSI)
- RSF 51.11
- PRLD 58.44
- Support Level
- RSF $14.59
- PRLD $1.33
- Resistance Level
- RSF $14.89
- PRLD $1.63
- Average True Range (ATR)
- RSF 0.08
- PRLD 0.19
- MACD
- RSF 0.01
- PRLD 0.02
- Stochastic Oscillator
- RSF 52.86
- PRLD 45.12
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.